26 - Challenges in Early Discovery (S2E11)

Hey, everyone. Welcome back for another deep
dive. And today we're going to be looking into
something really fascinating, a drug discovery
success story. Yeah. Specifically, the development
of an HIV protease inhibitor. Right. And this
is like a detective story, really figuring out
how to stop this tiny but formidable foe. Yeah.
It's a great example of how scientists take an
abstract concept. in this case, understanding
a virus, and translate that knowledge into an
actual tangible solution, like a drug that can
actually fight the disease. Yeah, so not just
theory, we're going deep into like the nitty
-gritty of how a drug actually goes from concept
to reality. Absolutely. And to make it even more
intriguing, we'll compare this successful drug
to one that actually failed during development.
Oh, interesting. Even though it showed early
promise, so it'll be like the side -by -side
comparison of what separates a winner from a
dud. OK, I'm hooked already. We've got excerpts
from research papers, medicinal chemistry textbooks,
even a peek into preclinical drug development
handbooks. Wow. So where do we even begin with
a story like this? Well, let's set the stage.
Imagine HIV as like a microscopic machine, you
know, relentlessly trying to make copies of itself.
OK. One crucial tool in its arsenal is something
called protease. It's an enzyme that acts like
a pair of molecular scissors. Scissors, OK. That's
a good visual. What are they cutting? So HIV
protease, it snips long protein chains into smaller
functional pieces. And these pieces are essential
for the virus to mature and spread. So it needs
to do that in order to replicate. Exactly. And
if you block that, it's like disrupting a communication
pathway, preventing the virus from sending out
the signals it needs to replicate. Got it. So
if you can stop those scissors, you stop the
virus from replicating, that's where protease
inhibitors come in. Precisely. Scientists recognized
early on disrupting this process would be key
to fighting HIV. It's like, you know, choosing
the right battle to fight, going after a critical
vulnerability in the enemy's defenses. Right.
Target validation. Exactly. That makes sense.
But actually designing a molecule that can effectively
block HIV proteins, that's where the real challenge
lies. Oh, absolutely. It's not like scientists
can just, you know, grab any molecule off the
shelf and hope for the best. Right. This is where
drug design gets really interesting. It's a blend
of creativity and, you know, meticulous scientific
understanding. Scientists had to unravel the
3D structure of HIV protease, map out its shape,
how it interacts with the proteins it cuts. So
it's like building a lock and key where the key
is the drug molecule and the lock is that active
site of the protease. That's a great analogy,
but here's where things get even more intricate.
Early attempts at designing HIV protease inhibitors
focused on molecules that mimicked the natural
protein pieces that the protease usually cuts.
OK, so if it looks like the target, it should
fit into the active site, right? But I have a
feeling there's a bit coming. You read my mind.
The problem was these early inhibitors, being
so peptide -like, were quickly chewed up by the
body's own enzymes. It was like sending a soldier
into battle wearing a uniform made of paper.
It wouldn't last very long. So their own weapon
was getting destroyed before it could even reach
the enemy. Exactly. It was a major setback. Scientists
realized they needed a more durable weapon, something
that could withstand the body's defenses and
still reach its target. Right. This led to a
shift toward designing non -peptide like inhibitors
molecules that could bind to HIV protase, but
wouldn't be as easily degraded. So it's not just
about finding a molecule that binds. It has to
have the right properties to survive in the body
as well. Exactly. That's where this whole idea
of lead optimization comes in. Right. Think of
it like. refining a recipe. You start with a
basic idea, but then you tweak the ingredients,
the proportions, the cooking time, until you
achieve the perfect flavor and texture. In drug
development, those ingredients are the molecule's
properties. Okay, so what kind of properties
are we talking about? What makes a good drug
molecule recipe? Well, one key property is something
called metabolic stability. Basically, how quickly
the drug is broken down by the body. Remember
those early peptide -like inhibitors we talked
about? They had poor metabolic stability because
they were rapidly degraded by enzymes. Right,
like the paper uniform just disintegrating in
the rain. Exactly. So scientists had to find
ways to make the inhibitor more resistant to
those enzymes. But wouldn't that focus on metabolic
stability potentially overlook other important
properties of the drug? That's a great question,
and it highlights the delicate balancing act
in drug development. You have to consider a whole
range of properties, not just metabolic stability.
So what else is on the checklist? Well, you also
need to think about how well the drug is absorbed
into the bloodstream, how it distributes throughout
the body, and whether it reaches the target tissues
in sufficient concentrations. It sounds incredibly
complex, like trying to solve this multi -dimensional
puzzle where each piece has to fit perfectly
to create a successful drug. That's a great way
to put it. And to complicate matters further,
scientists also have to be mindful of potential
toxicity. Right. Even if a drug is effective,
it's no good if it causes harmful side effects.
So it's about finding that sweet spot, a drug
that's effective against the virus, able to survive
in the body, and safe for the patient. Exactly.
And finding that sweet spot often involves a
lot of trial and error, a lot of testing and
refining. To see how this plays out in the real
world, let's take a closer look at an HIV protease
inhibitor that successfully navigated this complex
development process. Okay, let's meet our star
player. What's the name of this successful drug?
This particular protease inhibitor is called
sequinavir. And its journey began, as we discussed,
with scientists identifying HIV protease as a
key target. They knew they had to find a way
to disrupt this molecular machine if they wanted
to effectively fight the virus. And sequinavir
was a molecule that ultimately emerged victorious.
It must have been a fierce competition. You could
say that Sequinevere's journey is a testament
to the power of scientific ingenuity and perseverance,
but as we'll see, it wasn't a straight path to
success. There were unexpected twists and turns,
moments of doubt, and even a few near misses
along the way. Ooh, suspense already is getting
good. Take us back to the beginning. How did
Sequinevere first come onto the scene? Well,
the story of sequinivir really picks up steam
in the lab, where scientists were hard at work
designing and testing potential proteus inhibitors.
And I'm guessing this wasn't a straightforward
process. What were some of the roadblocks they
encountered? As we talked about earlier... Those
early attempts at designing peptide -like inhibitors
hit a major snag. They were just too unstable
in the body, quickly broken down by enzymes before
they could reach their target. Right, we talked
about that. So how did they overcome this hurdle?
Did they have to completely rethink their approach
to drug design? They did have to get creative.
They couldn't just abandon the idea of targeting
HIV protease. So they needed a way to design
inhibitors that were less peptide -like and therefore
less susceptible to degradation. OK, so that's
a tough challenge. It's like trying to create
a new language that the body's enzymes don't
understand. That's a great analogy. Scientists
had to essentially trick the body design a molecule
that could still bind to HIV protease, but wouldn't
be recognized as a target for those pesky enzymes.
So how did they go about doing that? Did they
have some sort of molecular disguise kit? Well,
they didn't have a disguise kit, but they did
have a powerful tool at their disposal, medicinal
chemistry. This field combines organic chemistry
with an understanding of biological systems to
create new molecules with specific properties.
So they were like molecular architects. designing
and building these inhibitors from the ground
up, carefully choosing each atom and bond to
achieve the desired outcome. Precisely. They
had to consider not only how the molecule would
bind to HIV proteins, but also how it would interact
with the body's enzymes, how it would be absorbed
and distributed, and a whole host of other factors.
It sounds incredibly intricate, like a delicate
balancing act between so many different variables.
It certainly was. And as they tweaked and refined
their designs, they were constantly testing and
evaluating their pro - This wasn't a one and
done process. They were constantly generating
data, analyzing the results, and using that information
to guide their next steps. So they weren't afraid
to go back to the drawing board if something
wasn't working? Not at all. In fact, that's a
hallmark of successful drug discovery, the willingness
to embrace failure as a learning opportunity.
They knew that every experiment, even the ones
that didn't yield the desired results, was bringing
them closer to their goal. It's like they were
detectives following each clue, each piece of
data until they cracked the case. I like that
analogy. And remember, we're talking about a
time before the advent of high -throughput screening
and other technologies that have since revolutionized
drug discovery. Oh, wow. So they were doing all
of this manually testing one molecule at a time.
To a large extent, yes. It was a painstaking
process that required a lot of patience and persistence.
Wow. That's incredible. It really underscores
the dedication and ingenuity of those early pioneers
in HIV drug discovery. Absolutely, and as they
meticulously piece together their molecular puzzle,
they started to see some promising leads emerge.
One of these leads would eventually become sequinivir.
Okay, so we've got our hero sequinivir stepping
into the spotlight. What were its vital stats?
What made it stand out from the crowd of other
potential inhibitors? Well, early tests showed
that sequinivir had a strong affinity for HIV
protease, meaning it bound tightly to its target.
That's a crucial first step, of course. Right.
It has to be able to grab onto the protease and
hold on tight to prevent it from doing its job.
But binding affinity is only part of the story,
right? What else was going for sequineavir? Remember
those metabolic stability studies we discussed?
Well, sequineavir performed admirably in those
tests as well. OK. It wasn't as easily broken
down by enzymes, meaning it could potentially
last longer in the body and have a greater chance
of reaching its target. So it was shaping up
to be a strong contender, good binding affinity,
decent metabolic stability. What happened next?
Well, as promising as sequineavir looked in the
lab, The real test was how it would behave in
living organisms. Right, because what happens
in a test tube doesn't always translate perfectly
to what happens in a complex biological system.
Exactly. So the next stage involved testing sequinovir
in animal models to see how it was absorbed,
distributed, metabolized, and eliminated. Basically,
they wanted to get a feel for its pharmacokinetic
profile. OK, so it was time to see if sequinovir
could perform. on the real battlefield, not just
in the controlled environment of the lab. What
did those animal studies reveal? Well, the results
were encouraging, but they also revealed a potential
challenge. While sequinevir was generally well
tolerated, its bioavailability, the amount of
drug that actually reaches the bloodstream was
somewhat limited. So even though it showed promise
in the lab and in animal models, there was a
chance that it wouldn't be absorbed well enough
in humans to be effective. That's a tricky situation.
It was, and it's a common problem in drug development
sometimes. A drug that looks great on paper just
doesn't quite make it over that final hurdle.
But the researchers weren't ready to give up
on sequinavir just yet. They knew they had a
potential game changer on their hands. So they
set out to find a way to improve its bioavailability.
OK, so how did they boost its chances? Was there
some secret ingredient they could add to the
mix? Well, it wasn't a secret ingredient per
se, but it did involve a clever strategy, a combination
therapy. Intriguing. Tell me more. They discovered
that by combining sequinovir with another drug
called ratonavir, they could significantly enhance
its bioavailability. Ratonavir inhibits an enzyme
that breaks down sequinovir, essentially allowing
it to stay in the bloodstream longer and reach
higher concentrations. Wow. That's a brilliant
workaround. It's like giving sequinivir a bodyguard
to protect it from those degrading enzymes. That's
a great way to think about it. This combination
therapy proved to be a game changer paving the
way for sequinivir's eventual approval as an
HIV treatment. This is a truly inspiring story
of scientific ingenuity and perseverance, but
you mentioned earlier that we'd also be looking
at an example of an HIV protease inhibitor that
didn't make it. Can you tell us about that? Certainly,
while sequinovir stands as a testament to the
power of rational drug design and lead optimization,
there are other HIV protease inhibitors that
faced a different fate. One such example is a
compound that never even made it to clinical
trials. Oh, wow. It failed even before reaching
human testing. What happened? Well, during preclinical
testing, researchers discovered that this particular
protease inhibitor exhibited significant toxicity
to heart cells. so it was attacking the very
cells it was supposed to be protecting. That's
a serious problem. Yes, and unfortunately this
toxicity was severe enough to halt further development
of the drug despite its potent anti -HIV activity.
The risk of cardiac side effects was deemed too
high to justify moving forward with human trials.
This is a stark reminder that drug development
is a delicate balancing act. You need a drug
that's effective against the disease but also
safe for the patient. Exactly. And sometimes,
despite the best efforts, a drug candidate reveals
unforeseen toxicities that preclude its further
development. Comparing sequinavir's success with
the failure of this other protease inhibitor
highlights the critical factors that can make
or break a drug. I'm curious, what were those
key differentiating factors? What set sequinavir
apart from the one that failed? Well, in Sequitiver's
case, meticulous lead optimization played a crucial
role. Scientists systematically assessed its
properties, including metabolic stability, absorption
distribution, and potential for toxicity. They
fine -tuned its structure to achieve a balance
between efficacy and safety. So they were constantly
evaluating and adjusting their strategy based
on the data they were gathering. Precisely. They
were adapting their approach in real time, responding
to the challenges as they arose. This iterative
process of testing and refining is at the heart
of successful drug development. And in the case
of the Proteus inhibitor that failed, did they
miss something during the lead optimization stage?
Did they not? adequately test for cardiac toxicity?
It's not always a case of missing something.
Sometimes toxicities emerge unexpectedly, even
with rigorous testing. Remember, preclinical
studies are often conducted in animals, which
might not perfectly predict how a drug will behave
in humans. So even with all the advances in drug
design and testing, there's still an element
of uncertainty. Absolutely. Drug development
is a complex and challenging endeavor, and there's
always the possibility of unforeseen hurdles.
But by learning from both successes and failures,
scientists can continuously improve their strategies
and increase the chances of bringing safe and
effective drugs to patients. This has been incredibly
insightful. we've really gotten a glimpse into
the intricate world of drug development with
all its triumphs and setbacks. Indeed, and I
think it's important to emphasize that even seemingly
small changes to a drug's structure can have
a huge impact on its success or failure. It's
a testament to the power of chemistry and the
dedication of scientists who work tirelessly
to develop life -saving medications. Well, we've
covered a lot of ground in this first part of
our deep dive. We've explored the challenges
of designing HIV protease inhibitors. the intricate
process of lead optimization, and the delicate
balancing act between efficacy and safety. But
there's so much more to unpack. Indeed, we've
only just begun to scratch the surface of this
fascinating story. We'll be back soon to delve
even deeper into the world of drug discovery
success. You know what's fascinating about SAC
Queen of Year success? It really highlights the
importance of adaptability in drug discovery.
Adaptability. What do you mean by that? Well,
scientists encountered several unexpected challenges
along the way, like that bioavailability issue
we discussed. Right. They could have easily given
up when they realized saquine wasn't being absorbed
well enough, but instead they found a creative
solution through combination therapy. Yeah, that's
a great point. It wasn't a straight line from
idea to finished. drug. Right. It sounds like
they had to constantly adjust their approach
based on the data they were gathering. Exactly.
And that's a crucial lesson for anyone involved
in drug discovery. You know, the willingness
to pivot, to try new things, to not be afraid
to deviate from the original plan when the data
suggests a different course of action. So being
a good drug hunter is as much about being flexible
and resourceful as it is about scientific expertise.
Absolutely. It's a blend of scientific rigor
and creative problem solving. Sometimes the most
groundbreaking discoveries come from those unexpected
detours, those moments where you have to think
outside the box. That's really inspiring. It
reminds me of a quote I once heard. The greatest
discovery of all time is that a person can change
his future by merely changing his attitude. I
like that it applies perfectly to the world of
drug discovery. And speaking of changing attitudes,
there's another aspect of sequinivir's development
that I think is worth highlighting the shift
in thinking about drug targets. Oh, interesting.
How did the understanding of drug targets evolve
during this time? Well, when scientists first
started working on HIV treatments, they focused
primarily on targeting viral enzymes, like reverse
transcriptase and protease. OK. These enzymes
are essential for the virus's life cycle, so
blocking them seemed like the most logical approach.
Makes sense to go after the key players, disrupt
the enemy's operations. But you said there was
a shift in thinking what changed. As scientists
learn more about HIV, they realize that the virus
is a master of disguise and adaptation. It can
mutate rapidly developing resistance to drugs
that target a single enzyme. Ah, so it's like
a moving target constantly changing its shape
to evade those molecular bullets that makes things
much trickier. Exactly. So scientists started
exploring new approaches looking beyond single
enzyme targets. They began to consider targeting
host factors, proteins in the human body that
HIV relies on for its survival. So instead of
attacking the virus directly, they started looking
for ways to weaken its support system. cut off
its supply lines. Precisely. It's a more indirect
approach, but one that holds a lot of promise
for overcoming drug resistance. OK. The idea
is to target cellular pathways that are crucial
for HIV, but not essential for human cell survival.
That's fascinating. It's like cutting off the
enemy's food supply without harming your own
troops. But I imagine targeting host factors
comes with its own set of challenges, right?
You're right. It's a more delicate balancing
act. You have to ensure that inhibiting the host
factor doesn't disrupt normal cellular processes
and cause harmful side effects. So it's like
walking a tightrope between effectiveness and
safety. But if scientists can pull it off, it
could be a game changer in the fight against
HIV. Absolutely. It's one of the most exciting
frontiers in HIV drug development today, and
it speaks to the constant evolution of scientific
thinking, the willingness to challenge old assumptions
and explore new avenues. This is really incredible.
It's like we're witnessing a scientific arms
race with scientists constantly developing new
strategies to outmaneuver this elusive virus.
That's a great analogy. And just like in any
arms race, the development of new weapons, or
in this case, new drugs, often leads to countermeasures
from the enemy. Meaning HIV will likely find
ways to develop resistance to these new host
factor inhibitors, just like it did with earlier
drugs. It's certainly a possibility, but scientists
are already thinking ahead, trying to anticipate
those moves and develop even more sophisticated
strategies to stay one step ahead. So it's a
never ending battle. a constant back and forth
between human ingenuity and viral evolution.
You could say that, but that's what makes this
field so exciting. There's always a new challenge
to overcome, a new mystery to unravel and the
stakes couldn't be higher. Well said. And I have
to say this conversation has given me a whole
new appreciation for the incredible complexity
and ingenuity involved in drug discovery. It's
a truly remarkable process. And as we've seen
with South Queen of Years story, it's one that's
driven by passion, perseverance and the unwavering
belief that we can find solutions to even the
most formidable challenges. This deep dive has
been incredibly illuminating. We've explored
the triumphs and setbacks of HIV drug discovery,
witnessed the evolution of scientific thinking
and glimpsed into the future of this ever -evolving
field. It's been a pleasure sharing these insights
with you, and I hope it's inspired our listeners
to learn more about this fascinating world where
science and human ingenuity converge to create
life -saving solutions. Absolutely. But before
we wrap up this episode, there's one more area
I'd like to touch upon, the role of collaboration
in drug discovery. That's a great topic. Collaboration
is absolutely essential in this field. No single
scientist, no single lab, no single company can
do it alone. It requires a collective effort,
a pooling of knowledge and resources from across
disciplines and organizations. So it's like a
global scientific community coming together to
tackle these complex challenges. Precisely. And
we see this collaborative spirit at play in so
many aspects of drug discovery, from the initial
stages of target identification to the clinical
trials that ultimately determine a drug's fate.
Can you give us some specific examples of how
this collaboration plays out in the real world?
Certainly one example is the sharing of data
and research findings. Scientists often publish
their work in scientific journals, making their
discoveries accessible to others in the field.
So it's like a giant open source project where
everyone contributes their piece of the puzzle,
and together they build a more complete picture.
That's a great way to think about it. And beyond
publications, there are also numerous conferences
and workshops where scientists from all over
the world gather to share their latest findings,
discuss challenges, and brainstorm new ideas.
It sounds like a vibrant indict - community constantly
pushing the boundaries of knowledge and innovation.
It truly is and these interactions these exchanges
of ideas and perspectives are often the spark
that ignites new discoveries. So it's not just
about the hard science it's also about the human
connections the relationships that are forged
through these collaborations. Absolutely. Science
is a human endeavor driven by curiosity, passion,
and the desire to make a difference in the world.
And those qualities are amplified when people
come together, share their knowledge, and work
towards a common goal. This has been such an
enlightening conversation. It's clear that collaboration
is the lifeblood of drug discovery, fueling innovation
and accelerating progress. It's been a pleasure
exploring this topic with you. And I think it's
important to remember that behind every successful
drug, there's a team of dedicated scientists,
clinicians, and regulatory experts all working
together to improve human health. Well said.
And as we wrap up this part of our deep dive,
I'm struck by the incredible journey we've taken.
We've explored the intricacies of HIV proteins,
the challenges of drug design, the importance
of adaptability and collaboration, and the promise
of new approaches like host factor targeting.
It's been quite a ride, and we've only just begun
to scratch the surface of this fascinating field.
I'm eager to see what other discoveries and breakthroughs
await us in the future. I show your enthusiasm.
The world of drug discovery is constantly evolving,
and I have no doubt that there are many more
exciting chapters yet to be written. We'll be
back soon to delve even deeper into this fascinating
world. You know, as we were talking about all
of these complexities of drug discovery, I keep
thinking about just the sheer amount of testing
and analysis that goes into developing a single
drug. Yeah, it's really mind -boggling when you
consider the number of molecules that are screened
and evaluated before even a single drug candidate
emerges. It's like searching for a needle in
a haystack, but on a molecular scale. Right.
And even when you find that needle, There's no
guarantee it will work as intended. Absolutely.
It's a high stakes game with a lot of potential
pitfalls along the way. Right. But thankfully
the tools and techniques for drug discovery are
constantly evolving, you know, becoming more
sophisticated and efficient. Speaking of tools,
you mentioned earlier that technologies like
high throughput screening have revolutionized
drug discovery. Can you tell us a bit more about
that? Sure, high throughput screening, or HTS,
it allows scientists to rapidly test thousands,
even millions of compounds, against a specific
target like HIV protease. Wow, so it's like having
a robot army of scientists working around the
clock conducting experiments at an incredible
pace. That's a great analogy. HTS has dramatically
accelerated the early stages of drug discovery,
helping scientists identify promising leads much
faster than traditional methods. That's amazing.
But I imagine it still takes a lot of work to
go from a promising lead to an actual drug that
can be used to treat patients. Oh, absolutely.
HTS is just the first step in a long and complex
journey. Once a potential drug candidate is identified,
it undergoes a very rigorous series of tests
to evaluate its safety and effectiveness. So
it's like putting the drug candidate through
boot camp. testing its limits and making sure
it's up for the challenge. That's a grilly to
put it. These tests include preclinical studies
in animals followed by clinical trials in humans
and at each stage there's a possibility that
the drug candidate will fail to meet the required
standards. So even with all these advances in
technology and screening methods there's still
a high degree of uncertainty in drug development.
There is. It's a humbling reminder that we're
dealing with very complex biological systems
and there's always the potential for unexpected
outcomes. But despite the challenges, the progress
that's been made in HIV drug discovery over the
past few decades is truly remarkable. It really
is. It's incredible. It's a testament to the
dedication and ingenuity and collaborative spirit
of scientists worldwide. Yeah. And as we wrap
up this deep dive, I'm left with a sense of awe
and wonder at this intricate world of drug discovery.
It's been a pleasure exploring this world with
you. And I think the key takeaway is that drug
discovery is a very dynamic and ever -evolving
field. It's driven by this relentless pursuit
of knowledge and a commitment to improving human
well -being. Well said. And I want to thank our
listeners for joining us on this fascinating
exploration. We hope you've gained a deeper appreciation
for the complexities and wonders of drug discovery.
And as always, we encourage you to continue learning
and exploring this ever -fascinating world. Who
knows what groundbreaking discoveries await us
just around the corner. That's right, so keep
that curiosity alive and we'll catch you on the
next deep dive. Until then, stay curious and
keep learning.